Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAshington Innov Regulatory News (ASHI)

Share Price Information for Ashington Innov (ASHI)

Share Price is delayed by 15 minutes
Get Live Data
0.85    0.00 (0.00%)
Bid:
0.70
Ask:
1.00
Spread: 0.30 (42.857%)
Market Cap: £617.08k
ASHI Live PriceLast checked at - London Stock Exchange

Intraday Ashington Innov Share Chart

Update on Cell Therapy and Calon Discussions

5 Sep 2023 07:00

RNS Number : 3475L
Ashington Innovation PLC
05 September 2023
 

Press Release

 

5 September 2023

 

Ashington Innovation plc

 

("Ashington" or "the Company") 

 

Update on Cell Therapy Ltd and Calon Cardio-Technology Ltd Discussions

 

Change of Broker

 

Ashington Innovation plc (LSE: ASHI; FSE: 6FW), a special purpose acquisition company, announces that further to the announcement of August 24, the Company continues to pursue negotiations to acquire Cell Therapy Limited ('Cell Therapy') and Calon Cardio-Technology Limited ('Calon') in accordance with the signed heads of terms.

 

By way of clarification, the proposed acquisition of Calon is dependent on a successful close of the Cell Therapy transaction. However, the proposed acquisition of Cell Therapy is not dependent on an acquisition of Calon.

 

Ashington can confirm that discussions have continued between the parties and that the Company is continuing its formal due diligence process. As no binding agreement has yet been reached, the Company cannot guarantee that either proposed acquisition will complete. 

 

Ashington also announces that following a breach of confidentiality by its broker, SI Capital, the appointment of SI Capital has been terminated and the Company is seeking to appoint a new sole broker experienced in the transactions being considered which is in line with its broader strategy to create a material regenerative medicine group.

 

The Company will provide further updates as and when appropriate.

 

For further information please contact:

 

Ashington Innovation plc

David Orchard

General Counsel

via Tancredi +44 207 887 7633

Tancredi Intelligent Communication

Media Relations

Helen Humphrey

Charlie Hobbs

Jasmine Gadhavi

ashington@tancredigroup.com

+44 7449 226 720

+44 7897 557 112

+44 7931 435 236

 

About Ashington Innovation plc

Ashington Innovation PLC is a special purpose acquisition company (SPAC), formed with the intention of acquiring businesses operating in the technology sector.

 

The Company believes that in the increasingly fast-changing global environment there will be an abundance of opportunities to acquire existing businesses in the technology sector, and in particular businesses that possess and utilise proprietary technologies and own applicable intellectual property.

 

The Company is not limited to any specific geographic region in identifying its target companies.

 

www.ashingtoninnovationplc.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFFFSFAIISIIV
Date   Source Headline
26th May 20264:45 pmRNSNotice of Annual General Meeting
30th Apr 20267:00 amRNSAnnual results
5th Dec 20255:20 pmRNSNotice of General Meeting
30th Sep 20257:00 amRNSInterim results
22nd Jul 20251:40 pmRNSResults of General Meeting
3rd Jul 20259:55 amRNSNotice of GM
9th Jun 20254:20 pmRNSResults of Annual General Meeting
15th May 20254:00 pmRNSNotice of Annual General Meeting
30th Apr 20257:00 amRNSAnnual Report
4th Oct 20246:15 pmRNSTR-1: Standard notification of major holdings
4th Oct 20246:15 pmRNSTR-1: Standard notification of major holdings
30th Sep 20247:00 amRNSInterim results
15th Aug 20244:20 pmRNSTR-1: Standard notification of major holdings
31st Jul 20247:00 amRNSRetrospective applications and corrections
25th Jul 20247:00 amRNSFundraise
17th Jun 202412:50 pmRNSResults of Annual General Meeting
24th May 20247:00 amRNSPosting of Annual Report and Notice of AGM
30th Apr 20246:19 pmRNSAnnual results
25th Jan 20247:30 amRNSRestoration - Ashington Innovation PLC
24th Jan 20247:00 amRNSTermination of Proposed Reverse Takeover
12th Jan 202412:30 pmRNSResults of Annual General Meeting
20th Dec 20232:00 pmRNSPosting of Annual Report and Notice of AGM
20th Dec 20231:15 pmRNSIssue of Equity
20th Dec 20237:00 amRNSAppointment of New Auditors
8th Nov 20233:30 pmRNSBoard changes
16th Oct 20237:00 amRNSAppointment of Non-Executive Director
5th Sep 20237:00 amRNSUpdate on Cell Therapy and Calon Discussions
24th Aug 20237:00 amRNSHeads of Terms Signed for the Acquisition of Calon
21st Aug 20237:00 amRNSDual Listing on the Frankfurt Stock Exchange
17th Aug 20238:10 amRNSHeads of Terms Signed
17th Aug 20237:30 amRNSSuspension - Ashington Innovation PLC
16th Aug 20237:00 amRNSBoard Change
9th Aug 202312:26 pmRNSChange of Accounting Reference Date
6th Jun 20238:01 amRNSAshington - Admission to trading on the LSE

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.